Paper913025
Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.
Pond SM and 2 others. Clin Pharmacol Ther, 1977. Cited by 89 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole. Papers, record 913025. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/913025
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Oxyphenbutazone | Major topic |
| Phenylbutazone | Major topic |
| Sulfaphenazole | Major topic |
| Tolbutamide | Major topic |
| Adult | |
| Depression, Chemical | |
| Drug Interactions | |
| Half-Life | |
| Humans | |
| Male | |
| Time Factors |
Source PubMed
Cited by33
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 89 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 30,910,785 | An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical Trials. | Drug Metab Dispos | 2019 | https://conductscience.org/library/papers/30910785 | PubMed |
| 29,119,333 | Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam. | Eur J Drug Metab Pharmacokinet | 2018 | https://conductscience.org/library/papers/29119333 | PubMed |
| 21,234,089 | Matching the Drug to the Patient: The rational use of antiarthritic drugs. | Can Fam Physician | 1991 | https://conductscience.org/library/papers/21234089 | PubMed |
| 19,214,275 | Applying organ clearance concepts in a clinical setting. | Am J Pharm Educ | 2008 | https://conductscience.org/library/papers/19214275 | PubMed |
| 11,678,793 | Systemic bioavailability of fluticasone proprionate. | Br J Clin Pharmacol | 2001 | https://conductscience.org/library/papers/11678793 | PubMed |
| 10,991,840 | Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect. | Antimicrob Agents Chemother | 2000 | https://conductscience.org/library/papers/10991840 | PubMed |
| 9,663,807 | Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. | Br J Clin Pharmacol | 1998 | https://conductscience.org/library/papers/9663807 | PubMed |
| 9,160,172 | Clinical pharmacokinetics of tretinoin. | Clin Pharmacokinet | 1997 | https://conductscience.org/library/papers/9160172 | PubMed |
| 9,068,933 | A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. | Clin Pharmacokinet | 1997 | https://conductscience.org/library/papers/9068933 | PubMed |
| 8,452,660 | Adverse drug interactions with nonsteroidal anti-inflammatory drugs (NSAIDs). Recognition, management and avoidance. | Drug Saf | 1993 | https://conductscience.org/library/papers/8452660 | PubMed |
| 8,424,795 | Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. | Biochem J | 1993 | https://conductscience.org/library/papers/8424795 | PubMed |
| 8,186,538 | Nonsteroidal anti-inflammatory drugs. Differential use in older patients. | Drugs Aging | 1994 | https://conductscience.org/library/papers/8186538 | PubMed |
| 8,186,058 | Plasma protein binding displacement interactions--why are they still regarded as clinically important? | Br J Clin Pharmacol | 1994 | https://conductscience.org/library/papers/8186058 | PubMed |
| 7,741,982 | Antihyperglycaemic agents. Drug interactions of clinical importance. | Drug Saf | 1995 | https://conductscience.org/library/papers/7741982 | PubMed |
| 7,437,261 | A comparative study of antipyrine and lignocaine disposition in normal subjects and in patients treated with enzyme-inducing drugs. | Br J Clin Pharmacol | 1980 | https://conductscience.org/library/papers/7437261 | PubMed |
| 7,213,531 | Effect of naproxen on glucose metabolism and tolbutamide kinetics and dynamics in maturity onset diabetics. | Br J Clin Pharmacol | 1981 | https://conductscience.org/library/papers/7213531 | PubMed |
| 7,175,701 | Physiologically based pharmacokinetics of drug-drug interaction: a study of tolbutamide-sulfonamide interaction in rats. | J Pharmacokinet Biopharm | 1982 | https://conductscience.org/library/papers/7175701 | PubMed |
| 7,106,168 | The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination. | Eur J Clin Pharmacol | 1982 | https://conductscience.org/library/papers/7106168 | PubMed |
| 7,030,708 | Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2. | Drugs | 1981 | https://conductscience.org/library/papers/7030708 | PubMed |
| 6,860,533 | Evidence for a dual action of sulphinpyrazone on drug metabolism in man: theophylline-sulphinpyrazone interaction. | Br J Clin Pharmacol | 1983 | https://conductscience.org/library/papers/6860533 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CYP4F3 | 4,051 | PubTator's text mining | https://conductscience.org/library/genes/4051 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/913025
GET https://conductscience.org/api/papers/v1/913025/cited_by?page=2